ORSENIX
Orsenix is a clinical-stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. It is committed to transforming cancer treatment with innovative oral therapies that give patients the freedom to live their everyday lives.
ORSENIX
Industry:
Biotechnology Life Science Medical
Address:
Wilmington, Delaware, United States
Country:
United States
Status:
Active
More informations about "Orsenix" on Search Engine
Orsenix Company Profile - Office Locations, Competitors …
Orsenix is a clinical-stage biotech company focusing on oral therapies to treat cancer. It develops a capsule form of arsenic trioxide for acute promyelocytic leukemia and other …See details»
Orsenix LLC | CipherBio
Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. At Orsenix, we …See details»
Syros Pharmaceuticals acquires Orsenix - 2020-12-07
Overview. Acquired Organization: Orsenix Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide. Acquiring Organization: Syros …See details»
Syros Acquires Clinical-Stage Drug Candidate for Acute …
Dec 5, 2020 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression …See details»
Orsenix - The Pharma Letter
Orsenix. "Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers." "Our investigational ATO, ORH-2014, is a …See details»
Syros Acquires Clinical Candidate for the Treatment of …
Dec 7, 2020 Rare Daily Staff. Syros Pharmaceuticals has acquired Orsenix’ ORH-2014, a targeted clinical-stage drug candidate that has the potential to dramatically reduce the …See details»
Syros acquires clinical-stage drug candidate for acute …
Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly …See details»
Syros acquires Orsenix’s SY-2102 drug candidate for APL treatment
Dec 9, 2020 In recent developments, Syros Pharmaceuticals, Inc, a Cambridge-headquartered biopharmaceutical organization that focuses on developing treatments …See details»
Orsenix Presents Positive Final Phase 1 Study Results for Lead ...
Jun 18, 2019 Founded in 2014 by respected discovery scientist, Kris Vaddi PhD, Orsenix is a clinical stage biotech company committed to transforming cancer treatment with …See details»
Orsenix (SY-2101) Company Profile 2024: Valuation, Investors ...
Orsenix (SY-2101) Overview. Update this profile. Status. Acquired/ Merged. Latest Deal Type. Asset Purch. Financing Rounds. 1. General Information. Description. Portfolio of …See details»
Orsenix - Products, Competitors, Financials, Employees, …
People. About Orsenix. Orsenix is a clinical-stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other …See details»
Orsenix Presents Positive Final Phase 1 Study Results for Lead ...
Jun 18, 2019 Founded in 2014 by respected discovery scientist, Kris Vaddi PhD, Orsenix is a clinical stage biotech company committed to transforming cancer treatment with …See details»
Syros Pharmaceuticals After The Orsenix Deal - Seeking Alpha
Dec 29, 2020 Healthcare. Syros Pharmaceuticals After The Orsenix Deal. Dec. 29, 2020 1:44 AM ET Syros Pharmaceuticals, Inc. (SYRS) Stock 5 Comments. 5 Likes. William …See details»
Orsenix, LLC - Drug pipelines, Patents, Clinical trials - Synapse
Private Company |. Delaware, United States. |. www.orsenix.com. Last update 01 May 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding (NIH) …See details»
Oral arsenic trioxide ORH-2014 pharmacokinetic and
ORH-2014 is a novel, oral arsenic trioxide formulation, consisting of micron-size drug particles with rapid dissolution and high bioavailability. We conducted a multicenter …See details»
Chemical fact sheets: Arsenic - World Health Organization (WHO)
May 18, 2022 Chapter 12 of the Guidelines for drinking-water Quality (GDWQ) includes fact sheets on chemical contaminants, based on comprehensive review documents published …See details»
Chemical Safety and Health - World Health Organization (WHO)
Apr 1, 2016 Effects – which can take years to develop depending on the exposure level – include skin lesions, peripheral neuropathy, gastrointestinal symptoms, diabetes, …See details»
Exposure to Arsenic: a major Public Health Concern
28 October 2019. | Publication. Download (99 kB) Overview. Soluble inorganic arsenic is highly acutely toxic. Intake of inorganic arsenic over a long period can lead to chronic …See details»
Syros Acquires Clinical-Stage Drug Candidate for Acute …
Dec 5, 2020 Syros has made an upfront cash payment of $12 million to Orsenix. In addition, Orsenix is eligible to receive a $6 million regulatory milestone related to the …See details»
New bill aims to limit harmful heavy metals found in baby food
5 days ago US lawmakers plan to introduce a bill Thursday that aims to limit the amount of heavy metals found in baby food through stronger regulation and enforcement by the US …See details»